Hypertension and Ischemic Stroke After Aflibercept for Retinopathy of Prematurity
Received 24 April 2020
Accepted for publication 23 June 2020
Published 3 July 2020 Volume 2020:13 Pages 243—247
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Scott Fraser
Fatemeh Bazvand,1 Elias Khalili pour,1 Golnaz Gharehbaghi,2 Hooshang Faghihi,1 Alireza Khodabandeh,1 Mohammadreza Mehrabi Bahar,1 Hamid Riazi-Esfahani1
1Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran; 2Ali Asghar Children’s Hospital, Iran University of Medical Sciences, Tehran, Iran
Correspondence: Mohammadreza Mehrabi Bahar
Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Farabi Eye Hospital, Qazvin Square, South Kargar Street, Tehran 1336616351, Iran
Background: Retinopathy of prematurity is the leading cause of preterm infants’ blindness. The preferred method for the management of aggressive posterior ROP is the anti-vascular endothelial growth factor (anti-VEGF). However, systemic and ocular adverse effects of anti-VEGF drugs remain a concern.
Case Presentation: A case report of a preterm infant with a history of hypertension underwent intravitreal injection of aflibercept at the 50-week postmenstrual age because of aggressive posterior retinopathy of prematurity (ROP) in both eyes. Seven days after the intravitreal administration of aflibercept, he has a hypertension crisis and an ischemic stroke. Serial fundoscopies implied complete arrest of vascularization till seven months after receiving treatment.
Conclusion: We report a case of an infant, with a history of hypertension, had an ischemic stroke just one week after the intravitreal injection of aflibercept for aggressive posterior ROP. We can conclude that in cases of preterm infants with systemic comorbidities, like uncontrolled hypertension, that predispose patients to thromboembolic events, we should be cautious about the potential increase in the risk of thromboembolic events after administration of anti-vascular endothelial growth factor agents (anti-VEGF), especially those with a longer half-life, like aflibercept.
Keywords: retinopathy of prematurity, aflibercept, intravitreal injection, stroke, cerebrovascular accident
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]